European Innovation Council

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Aplagon is a biopharmaceutical company focused on developing innovative antithrombotic medications aimed at addressing complications associated with vascular interventions, particularly blood vessel occlusions. The company specializes in creating biological mimetics of heparin proteoglycan, which are intended for the clinical management of thrombotic occlusions and ischemic reperfusion injuries. Aplagon's mission is to provide patients with effective treatment options that offer significant safety advantages, thereby fulfilling unmet medical needs in the field of vascular health.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

BOYDSense is a company based in South San Francisco, California, that specializes in developing non-invasive tools for measuring critical biomarkers through exhaled breath. Founded in 2015, the company focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns in human breath. This innovative approach aims to simplify the monitoring, screening, and risk stratification of chronic conditions, enabling medical professionals to diagnose and manage diseases more effectively.

Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques, including Google's TensorFlow, to enhance the diagnosis of brain-related diseases, particularly acute stroke. The platform facilitates timely and universal diagnosis by using non-contrast CT imaging, which eliminates the need for contrast CT scans and significantly reduces time-to-treatment. This capability enables radiologists to effectively communicate with hospitals, stroke units, and other healthcare professionals, thereby improving the overall clinical response to stroke cases. By focusing on specific pathologies, Methinks aims to achieve clinical excellence in the diagnosis and management of neurological conditions.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

PrediSurge is a software company that offers design and support solutions for physicians and medical device companies.

Cellevate AB is a biotech company based in Lund, Sweden, founded in 2014. It specializes in developing advanced 3D cell culture systems utilizing nanofiber scaffolds known as 3D NanoMatrix. These scaffolds facilitate the creation of realistic in-vitro models, which are essential for scientific research and development across various fields, including automotive, construction, defense, electronics, energy, environment, and healthcare. Cellevate's platform employs a patented manufacturing process to produce consistent and porous networks of nanofibers, enhancing the effectiveness of cell culture systems and supporting upstream bioprocessing efforts.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in developing innovative solutions for microsurgery, a field that operates at the limits of physical capabilities. The company's flagship product is a motion stabilizer system designed specifically for microsurgeons, which enhances surgical precision by filtering out tremors and providing exceptional control during procedures. This technology allows for hybrid microsurgical procedures that enable surgeons to utilize their own instruments, thereby reducing costs for hospitals. The Microsure motion stabilizer has demonstrated its effectiveness in clinical trials, including successful operations for lymphedema. By improving the quality of microsurgical procedures, the company aims to expand treatment options for patients and facilitate the development of new, highly accurate surgical techniques.

EyeControl is a pioneer in medical technology focused on innovative communication solutions for healthcare. The company has developed a unique device aimed at improving the quality of life for patients with locked-in syndrome, particularly those suffering from ALS. This device consists of a simple glass frame equipped with an infrared camera that connects to a compact computer. It translates the patients' blinks and eye movements into commands, which are then converted into speech through earphones and a speaker. By leveraging advanced technology, EyeControl addresses significant communication barriers, enabling patients to express their needs and preferences more effectively.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Senecio Robotics is a company focused on combating mosquito-borne diseases through innovative technology. Comprised of experts from the aerospace and defense sectors, the firm has developed advanced mosquito-sorting robots that automate the processes of sex sorting and sterilization of mosquitoes. Utilizing proprietary technology that integrates robotics and machine learning, Senecio Robotics identifies, separates, and sterilizes female mosquitoes, which are primarily responsible for transmitting diseases. This automation enables effective and scalable mosquito control strategies in regions affected by these health threats, contributing to a healthier future for communities. The company's name, inspired by the Senecio flower, symbolizes a commitment to fostering a better world for future generations.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Elgan Pharma is a biotechnology company specializing in neonatology, dedicated to addressing medical challenges and developmental issues faced by premature infants. The company is focused on developing innovative therapies utilizing nanotechnology to prevent visual impairment, a common and multifactorial problem in preterm babies. By targeting the specific needs of this vulnerable population, Elgan Pharma aims to enhance visual outcomes and reduce the risk of significant disabilities, ultimately supporting healthcare professionals in their efforts to improve the quality of life for these infants.

Cellbox Solutions is a technology company that specializes in innovative logistical solutions for the global BioMed industry. The company has developed a carbon dioxide incubator aimed at enhancing the storage, isolation, handling, and analysis of biological materials. This incubator supports the proper management of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the safe transport of living cells via roads, rails, or airways, Cellbox Solutions assists healthcare providers in their efforts to deliver advanced therapies and improve patient treatment outcomes.

Plasmacure is a Netherlands-based company that specializes in developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. Their patented solution effectively kills bacteria, stimulates cell proliferation, and enhances microcirculation, which helps reduce the risk of amputation. By addressing these critical aspects of wound healing, Plasmacure's technology aims to improve the quality of life for patients suffering from chronic wounds.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

Escala Medical is focused on developing a minimally invasive medical device aimed at treating pelvic organ prolapse (POP) in women. The company's innovative system offers a nonsurgical, incision-free, and mesh-free repair option that addresses the vaginal apex by connecting it to the sacrospinous ligament. This approach is designed to be safe, quick, and to preserve organ functionality while minimizing patient discomfort. The procedure can be performed in outpatient and office-based settings, providing a much-needed alternative for women suffering from POP.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Scandinavian Real Heart is a medical technology company focused on developing an innovative artificial heart designed to assist patients awaiting heart transplants. Their Total Artificial Heart (TAH) closely mimics the natural pumping mechanics, pressure ratios, and pulse of a healthy heart, aiming to provide improved functionality compared to existing options in the market. This device serves primarily as a transitional solution for individuals on the transplant waiting list, with the potential to save lives by addressing the urgent need for effective cardiac support.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

GrayMatters Health is a health technology company focused on developing digital therapeutics aimed at addressing mental disorders through the regulation of brain processes. By utilizing an approach grounded in neuroscience, the company provides solutions that enhance the efficacy, safety, and accessibility of mental healthcare. Their offerings empower healthcare professionals and patients alike, enabling individuals with neurological disorders to manage their conditions more effectively and conveniently. GrayMatters Health aims to bridge existing gaps in mental health treatment, promoting better outcomes for those affected by these challenges.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Syntach is a medical device company focused on improving the care of individuals with heart failure through the development of a cardiac support device. This innovative device aims to restore the impaired movement of the mitral valve and provide natural support to the heart. Syntach offers a permanent, active implant that can be inserted using a minimally invasive technique, making it smaller than existing left ventricular assist devices (LVADs). This design not only enhances the quality of life for patients but also reduces the risk of complications, benefiting both men and women who require cardiac support.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Brainhero is a life science company that specializes in home-based neurofeedback therapy aimed at addressing neurological impairments, particularly Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD). The company offers a playful approach to brain training, allowing children to learn how to control their brain activity through the measurement of brain waves using electroencephalogram (EEG) technology. This data is visualized in a user-friendly app, facilitating an engaging experience for young users. Brainhero's services extend beyond ASD and ADHD to include other neurological issues such as intellectual disabilities, epilepsy, and anxiety. Additionally, the company provides mobile neurofeedback training that helps improve concentration and relaxation, assisting medical practitioners in early detection of neurological problems and supporting appropriate medication management for patients.

Nano4Imaging GmbH, founded in 2011 and based in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimal invasive devices, such as catheters and guidewires. The company offers products like MRWire EmeryGlide, a guide wire compatible with magnetic resonance imaging (MRI), and the MagnaFy series, which includes coatings that enhance visibility under MRI, computed tomography (CT), and X-ray imaging. These innovations facilitate medical interventions and therapies, particularly in the treatment of cardiovascular diseases and during radiotherapy, allowing for precise monitoring of medical devices during procedures. By leveraging nanotechnology, Nano4Imaging aims to enhance diagnostic imaging capabilities for healthcare professionals.

Axiles Bionics is a Brussels-based company that specializes in manufacturing robotic ankle-foot prostheses aimed at enhancing the quality of life for lower limb amputees. Founded in 2018 as a spin-off from Brubotics at the Free University of Brussels, the company focuses on developing advanced prosthetic technology that combines the strength and flexibility of a human ankle with robotic features. This innovative approach enables individuals with limb disorders to experience improved movement and support through the next generation of bionic feet. Axiles Bionics is dedicated to advancing assistive robotics to meet the needs of amputees effectively.

AVATAR MEDICAL specializes in developing a virtual reality platform that creates 3D patient avatars from medical images. This innovative technology assists surgeons in visualizing complex medical data, evaluating surgical options, and enhancing training for medical fellows. By providing accurate and interactive representations of patients, the platform enables clinicians to better comprehend critical clinical information, ultimately improving the decision-making process in surgical planning. Additionally, AVATAR MEDICAL's approach fosters greater engagement with patients, allowing them to better understand their medical conditions and treatment options.

Akknatek specializes in developing innovative optical testing products aimed at improving postoperative management of intraocular lenses (IOLs). The company's patented lens reviewer technology enhances patients' visual outcomes, particularly for those experiencing dislocated IOLs following cataract surgery. By providing clear protocols for treatment, the lens reviewer minimizes the risk of unexpected refractive complications and decreases the need for additional refractive procedures. This streamlined approach to postoperative monitoring not only aids clinics in managing IOL placements but also fosters greater confidence in IOL implantations, ultimately benefiting patient care and outcomes.

Arspectra is a medical technology firm that focuses on unique augmented reality solutions for the healthcare industry.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

NC Biomatrix is focused on developing medical therapies aimed at restoring the natural biomechanics of the spine to address low back pain. The company offers a non-invasive treatment option that involves an injectable viscous gel designed to alleviate the underlying causes of lower back pain. By targeting the biomechanics of the spine, NC Biomatrix provides a novel solution for patients suffering from osteoarthritis and related conditions, improving their quality of life through effective pain management.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly focusing on MRI scanners. The company provides a cloud-based data analysis platform that ensures the calibration of images is traceable to standardized values. Its innovative cylindrical phantom design addresses the need for multiple sample vials during phantom preparation, allowing clinicians, medical physicists, and radiographers to obtain reproducible quantitative measurements of diseases across different patients, scanners, and clinics. This approach not only enhances the accuracy of MRI imaging but also holds the potential to reduce medical costs over time.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing high-prevalence pathologies and unmet medical needs. The company focuses particularly on multiple sclerosis, offering diagnostic kits that facilitate early diagnosis of the condition. These kits are designed for seamless integration into the clinical routines of hospitals and medical centers, enabling healthcare professionals to deliver accurate results. By improving diagnostic capabilities, ALA Diagnostics aims to enhance the quality of life for individuals affected by multiple sclerosis. The company leverages collaborations with public organizations to foster innovative projects and enhance its product offerings.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Precisis is a medical technology company based in Heidelberg, Germany, founded in 2004. The company focuses on developing innovative medical devices aimed at treating epilepsy and enhancing patients' quality of life. Their flagship product involves a device that delivers individualized brain stimulation through a surgical procedure. This device is precisely positioned beneath the scalp over the epileptic origin in the brain, allowing for targeted therapeutic currents to be directed at specific areas without direct contact with the brain. This approach aims to provide deep and focused stimulation to effectively manage epilepsy.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

Gate2Brain is an early-stage biotech company dedicated to enhancing drug delivery across biological barriers, particularly the blood-brain barrier, through a patented peptide-based technology. This innovative platform aims to transport therapeutics directly to the brain, thereby improving the efficacy of treatments for neurological diseases and reducing associated side effects. Additionally, Gate2Brain focuses on developing therapeutics that can address rare pediatric cancers, positioning itself as a key player in advancing medical solutions for challenging conditions.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

Cherry Biotech is a biomedical technology company specializing in Organ-on-Chip systems that facilitate drug discovery and personalized medicine. The company develops advanced microfluidic technologies to culture and replicate human organs under various physiological and pathological conditions. Additionally, Cherry Biotech provides temperature controllers to enable rapid temperature changes and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately mimicking the human cellular microenvironment, which is essential for drug development and toxicity assessments.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. By targeting the host mechanisms that viruses exploit, the company aims to create antiviral drugs that empower healthcare institutions to effectively treat a variety of viral infections. Through its innovative approach, Meletios Therapeutics seeks to fulfill significant medical needs in the field of infectious diseases.

Lattice Medical is a medical technology company based in Loos, France, founded in 2017. The company specializes in the design and manufacture of innovative prostheses for women who have undergone mastectomy due to breast cancer. Its flagship product, MATTISSE, addresses significant clinical and societal needs by enabling natural breast reconstruction. MATTISSE uses a combination of biomaterials and tissue engineering, including 3D printing, to create custom implants that regenerate autologous adipose tissue. This technology allows for a single surgical procedure, as the fully biodegradable implants dissolve after reconstruction, minimizing invasiveness and pain while reducing surgery time. Lattice Medical aims to replace traditional silicone-based implants with its advanced solutions, thereby enhancing the quality of life for women affected by breast cancer.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

VesselSens, headquartered in Bonn, Germany, specializes in medical technology. It develops and markets implantable sensor systems designed to detect restenosis, a common complication following stent implantation or balloon angioplasty. These wireless sensors, placed in coronary or peripheral arteries, monitor vascular constrictions in real-time, aiding doctors in timely diagnosis and treatment.

Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.